<?xml version="1.0" encoding="ISO-8859-1"?><rss version="2.0"><channel><title>Cap Decisif</title><link>http://www.capdecisif.com/</link><description>Fonds de capital-amorcage dans les entreprises innovantes et de hautes-technologies en Île-de-France</description><copyright>Cap Decisif, 2006</copyright><image>		<title>Cap Decisif</title>   		<url>http://www.capdecisif.com/rsslogo.gif</url>   		<link>http://www.capdecisif.com</link>  		</image><language>fr</language><managingEditor>jerome.snollaerts@capdecisif.com</managingEditor><webMaster>jerome.snollaerts@capdecisif.com</webMaster><pubdate>Thu, 05 Jun 2008 12:54:05 +0100</pubdate><item><title><![CDATA[Nanobiotix CEO Dr. Laurent Lévy is elected co-president of the French Technology Platform on Nanomedicine (FTPN)]]></title><link>http://www.capdecisif.com</link><pubDate>Thu, 05 Jun 2008 00:00:00 +0100</pubDate><description><![CDATA[For Immediate Release
Contact:
Ronald Trahan, APR
Ronald Trahan Associates Inc. 508-359-4005, x108
Nanobiotix CEO Dr. Laurent Lévy is elected co-president of the French Technology Platform on Nanomedicine (FTPN)

Podcast available at www.medtechmatters.com
PARIS, June 4, 2008-Nanobiotix, an emerging nanomedicine company focused on cancer therapy, announced today that its chief executive officer, Laurent Lévy, Ph.D., has been elected as co-president of the French Technology Platform on Nanomedicine (FTPN), effective immediately. 

FTPN organizes communication, collaborative work and meetings among the French-based nanomedicine community's stakeholders-such as companies, research institutes, universities, hospitals, and patient associations-with representatives from ministries, regional clusters, government agencies and research foundations.

"I am honored to serve as the co-president of FTPN," said Dr. Lévy.  "FTPN's mission is to help accelerate the development of nanomedicine into clinical practice for the benefit of patients. Moving forward, this evolving field of nanomedicine will be a great challenge, one that our committed board members are ready to undertake." 
 
FTPN is the counterpart to the European Technology Platform on Nanomedicine (ETPN) and works to ensure French-based participation in European collaborative projects.  Led by market needs and industrial developments, FTPN has the following goals: 
(1) identify and represent stakeholders; 
(2) support industrial R&D priorities and initiatives with a strong link and collaborative work with public-focused research; 
(3) allow emergence of innovative projects in accordance with national and local initiatives; 
(4) inform, and initiate dialogue with, patient associations and the general public;
and (5) link and promote work between regulatory agencies and nanomedicine stakeholders. 
 
FTPN's board of directors includes-co-presidents:  Dr. Lévy and Gérard Mathis, CSO, Cis-Bio; Patrice Marche representing INSERM and CNRS and Jean-Pierre Benoit representing clinical research; Patrick Boisseau, Executive Board member of the European Technology Platform on Nanomedicine; and, Pierre-Noël Lirsac, French representative to the European Technology Platform Nanomedicine Mirror Group 1.
 
Nanomedicine(2) is the application of nanotechnology to achieve breakthroughs in healthcare. It exploits the improved and often novel physical, chemical and biological properties of materials at the nanometer scale. Nanomedicine has the potential to enable early detection and prevention and to essentially improve diagnosis, treatment and follow-up of diseases.
 
1 Official representative from states member and associated states member from EU.
2 Source: ETPN, Strategic Research Agenda, November 2006.

ABOUT NANOBIOTIX
Nanobiotix is an emerging nanomedicine company combining dramatic advances in nanotechnology and molecular biology to develop nanoXray™- a technology platform that is expected to be turned 'on' and 'off' outside the body to selectively treat a variety of cancers safely and noninvasively.  Use of nanoXray is intended to resolve radiation therapy's biggest drawback: destruction of healthy tissue and its subsequent deleterious side effects when a high dose of Xray is necessary.  The core of a nanoXray nanoparticle is an inactive and inert substance-not a drug-that can be activated to locally (intratumor) increase the dose of Xray, which is then expected to lead to higher efficiency.  After nanoXraynanoparticles accumulate in the target tissues, a standard X-ray is applied that is intended to generate a local therapeutic effect, designed to destroy only the targeted tumor cells.  This mechanism suggests total control of the intended therapeutic effect.]]></description></item><item><title><![CDATA[ERYtech  Pharma inclut le dernier patient de son étude clinique de Phase II]]></title><link>http://www.capdecisif.com</link><pubDate>Thu, 15 May 2008 00:00:00 +0100</pubDate><description><![CDATA[ERYtech Pharma, société de biotechnologie française, annonce l’inclusion du dernier patient  dans 
son essai de phase II dans la rechute de la Leucémie Aigüe Lymphoblastique (LAL). 
 
Cet essai a pour but d’évaluer la pharmacocinétique, la pharmacodynamique et la tolérance du 
GRASPA®, nouveau produit d’ERYtech Pharma. Vingt quatre patients ont été inclus ; neuf adultes et 
neuf enfants ont reçu au moins une fois du GRASPA®, trois adultes et trois enfants ont reçu le produit 
de contrôle : L-Asparaginase (E.Coli) dans sa forme libre. 
 
Le Professeur Yves Bertrand, Administrateur de l'Institut d'Hématologie et d'Oncologie Pédiatrique de 
Lyon (IHOP), Président du Groupe Leucémie de l’Enfant au sein de l’European Organisation for 
Research and Treatment of Cancer (EORTC), et Investigateur Principal de l’essai se réjouit : «  Cet 
essai, qui a mobilisé un grand nombre de mes confrères français et belges, démontre leur vif intérêt et 
le besoin de disposer d’une asparaginase mieux tolérée et plus efficace dans le traitement de la LAL. 
Nous attendons avec impatience les résultats définitifs et restons mobilisés pour la suite du 
développement clinique du GRASPA®». 
 
« Les premiers résultats seront connus dans trois mois. La stratégie de développement, notamment 
pour les patients ne tolérant pas les autres formes d’asparaginases sera alors rapidement mise en 
œuvre » précise David Liens, Directeur Médical de la société. 
 
Yann Godfrin, Président du Directoire d’ERYtech Pharma tient à remercier tous les investigateurs et 
leurs collaborateurs pour leur implication et leur motivation, ainsi que le Dr Irène Philip, Responsable 
de L’Unité de Thérapie Cellulaire du Centre Léon Bérard (Lyon) pour sa collaboration dans la 
préparation des lots cliniques. Il ajoute : « Cet essai multicentrique en France et en Belgique, nous a 
également permis de valider avec succès la logistique de la délivrance de GRASPA®. Cette étape 
majeure pour ERYtech Pharma ouvre de belles perspectives ». 
 
A propos de GRASPA® (cliquer sur le lien pour visualiser la vidéo) 
 
GRASPA® est une nouvelle formulation de la L-asparaginase encapsulée à l’intérieur de globules 
rouges homologues. L’objectif du GRASPA® est de surmonter toutes les limitations combinées des 
formulations actuelles de la L-asparaginase grâce à une efficacité prolongée, une réduction de dose 
et un profil de sécurité amélioré. GRASPA® est développé pour les patients atteints de leucémies 
aigües lymphoblastiques, y compris ceux à risque (hypersensibles, patients âgés) ou développant des 
anticorps neutralisants. 
La L-asparaginase est un composant essentiel et irremplaçable des protocoles de chimiothérapies 
utilisés en clinique depuis plus de 30 ans pour le traitement des leucémies aigües lymphoblastiques. 
L’enzyme dégrade l’acide aminé plasmatique asparagine, élément essentiel à la croissance tumorale 
des lymphoblastes. Contrairement aux cellules normales, les cellules leucémiques ne peuvent pas 
produire leur propre asparagine, l’administration de L-asparaginase les privent de cet élément 
essentiel et entraine leur mort. 
Malgré une très grande efficacité anti-tumorale et l’existence de plusieurs formulations, les cliniciens 
demeurent insatisfaits en raison de sa toxicité élevée et son absence d’efficacité dans certains cas en 
raison de l’apparition d’anticorps neutralisants au fur et à mesure des administrations. 
 
A propos de GRASPALL 
 
GRASPALL est une étude clinique multicentrique de phase II évaluant le GRASPA®  dans le 
traitement des premières rechutes de leucémies aigües lymphoblastiques de l’enfant et l’adulte. 
L’objectif principal de cette étude comparative randomisée est de déterminer la relation entre la dose 
de GRASPA® administrée et la durée de la déplétion en asparagine plasmatique. Le protocole 
clinique est basé sur les recommandations de l’EORTC (COOPRALL). Les patients sont randomisés 
en 4 groupes : 3 doses de GRASPA® (50 UI/Kg, 100 UI/Kg ou 150 UI/Kg) sont testées, les patients 
du groupe contrôle reçoivent de la Kidrolase®. Les objectifs secondaires de l’étude sont d’évaluer la 
tolérance du GRASPA®, ses propriétés pharmacologiques et son immunogénicité. Les 24 patients de 
l’étude (12 enfants et 12 adultes) ont été recrutés dans 24 centres investigateurs, ouverts en France et 
en Belgique. 
 
A propos d’ERYtech Pharma (pour plus d’information, cliquer sur le lien) 
 
ERYtech Pharma est une société de biotechnologie développant une nouvelle génération de 
médicaments améliorant significativement l’espérance et la qualité de vie des patients. 
Pionnière dans l’encapsulation de molécules thérapeutiques dans les globules rouges, ERYtech 
Pharma développe un pipeline de solutions thérapeutiques innovantes basées sur sa technologie 
propriétaire et son expertise des propriétés physiologiques des érythrocytes. La société adresse des 
pathologies graves, des indications orphelines ou des sous-populations de patients notamment dans 
les domaines de l’hématologie, du cancer et des maladies métaboliques. 
Le produit le plus avancé, GRASPA®, a complété une étude de phase II dans les leucémies aigües 
lymphoblastiques, d’autres indications sont explorées notamment dans les tumeurs solides. Plusieurs 
autres produits sont également en cours de développement.]]></description></item><item><title><![CDATA[Autodesk Completes Acquisition of Kynogon SA]]></title><link>http://www.capdecisif.com</link><pubDate>Wed, 07 May 2008 00:00:00 +0100</pubDate><description><![CDATA[Grows Autodesk’s Videogame Middleware and Simulation Offering

SAN RAFAEL, Calif., May 7, 2008 — Autodesk, Inc. (NASDAQ: ADSK) today announced that it has completed the acquisition of Kynogon SA, the privately held maker of Kynapse artificial intelligence middleware. Autodesk announced its intent to acquire Paris-based Kynogon on February 19, 2008. Terms of the transaction were not disclosed.

Kynapse has been used to develop more than 65 AAA game titles, including Alone in the Dark 5, Crackdown, Fable 2 and The Lord of the Rings Online: Shadows of Angmar. Kynapse gives characters spatial awareness, enabling them to realistically navigate digital environments. As well, Kynapse is widely used in simulation industries.

“The acquisition of Kynogon extends Autodesk’s leadership in game development and simulation technology. We welcome Kynogon’s customers, partners, and employees to Autodesk,” said Marc Petit, Autodesk Media & Entertainment senior vice president. “The future of video games is about more believable characters and environments. Due to the increasing complexity of video games, developers are adopting commercial middleware solutions such as Kynapse and Autodesk HumanIK to improve game play and to stay on time and on budget.”

Autodesk for Games
Autodesk’s end-to-end solutions for game development include: Autodesk 3ds Max modeling, animation and rendering software; Autodesk Maya 3D modeling, animation and rendering software; Autodesk MotionBuilder character animation software; Autodesk Mudbox digital sculpting software; Autodesk HumanIK and Autodesk Kynapse middleware; and Autodesk FBX data interchange format. To learn more about Autodesk’s game development solutions, visit www.autodesk.com/games.

Safe Harbor Statement
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the impact of the acquisition on Autodesk's earnings per share, product offerings and the performance of its business. Factors that could cause actual results to differ materially include the following: difficulties encountered in integrating merged businesses; whether certain market segments grow as anticipated; the competitive environment in the software industry and competitive responses to the acquisition; and whether the companies can successfully develop new products or modify existing products and the degree to which these gain market acceptance.

Further information on potential factors that could affect the financial results of Autodesk are included in the company's annual report on Form 10-K for the year ended January 31, 2008, which is on file with the Securities and Exchange Commission.

About Kynogon SA
Kynogon develops and markets Kynapse, a unique artificial intelligence engine. Kynapse is used by the world's leading game developers such as Electronic Arts, Activision, Bethesda Softworks, Lionhead Studios, Midway, Real Time Worlds, SEGA, Sony Online Entertainment, Spark Unlimited, THQ and Turbine, for the development of their AAA titles. Kynapse has also been selected by industry leaders such as EADS and British Aerospace Systems as their preferred artificial intelligence solution. For more information please visit www.kynogon.com.]]></description></item><item><title><![CDATA[Autodesk signs definitive agreement to acquire Kynogon, maker of Kynapse—the leading game AI middleware.]]></title><link>http://www.capdecisif.com</link><pubDate>Wed, 20 Feb 2008 00:00:00 +0100</pubDate><description><![CDATA[AN RAFAEL, Calif., Feb. 19, 2008 — Autodesk, Inc. (NASDAQ: ADSK) today announced that it has signed a definitive agreement to acquire Kynogon SA, the privately held maker of Kynapse artificial intelligence middleware. Terms of the transaction were not disclosed.

Kynapse has been used to develop more than 65 AAA game titles, including Alone in the Dark 5, Crackdown, Fable 2 and The Lord of the Rings Online: Shadows of Angmar. Kynapse gives characters spatial awareness, enabling them to realistically navigate digital environments.

“The future of videogames is about sophisticated game play, with more believable characters and environments,” said Marc Petit, senior vice president, Autodesk Media & Entertainment. “Our goal is to simplify videogame development by providing cutting-edge tools to create, animate and integrate 3D assets into game engines. The acquisition of Kynogon is a key component in reaching this goal.”

Petit added, “Videogame technology is the beachhead for real-time simulation applications and advanced computing. In addition to game development, Kynogon’s products are being used for defense and security simulations, such as mission planning and military operations on urban terrain.”

Autodesk expects the acquisition to be completed within the next three months. The acquisition is subject to customary closing conditions. Autodesk will provide further details about the acquisition once the transaction has closed.  For more information please visit www.autodesk.com/kynogon.

Business Outlook
This transaction is expected to decrease targeted GAAP earnings per diluted share by $0.01 to $0.02 in fiscal 2009.  Excluding in-process R&D expenses and the amortization of acquisition-related intangibles, this transaction is expected to have no impact on targeted non-GAAP earnings per diluted share for fiscal 2009.

Safe Harbor Statement
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the impact of the acquisition on Autodesk's earnings per share, product offerings and the performance of its business. Factors that could cause actual results to differ materially include the following: difficulties encountered in integrating merged businesses; whether certain market segments grow as anticipated; the competitive environment in the software industry and competitive responses to the acquisition; and whether the companies can successfully develop new products or modify existing products and the degree to which these gain market acceptance.

Further information on potential factors that could affect the financial results of Autodesk are included in the company's reports on Form 10-K for the year ended January 31, 2007, and Form 10-Q for the quarter ended October 31, 2007 which are on file with the Securities and Exchange Commission.

About Kynogon SA
Kynogon develops and markets Kynapse, a unique artificial intelligence engine. Kynapse is used by the world's leading game developers such as Electronic Arts, Activision, Bethesda Softworks, Lionhead Studios, Midway, Real Time Worlds, SEGA, Sony Online Entertainment, Spark Unlimited, THQ and Turbine, for the development of their AAA titles. Kynapse has also been selected by industry leaders such as EADS and British Aerospace Systems as their preferred artificial intelligence solution. For more information please visit www.kynogon.com.

About Autodesk
Autodesk, Inc. is the world leader in 2D and 3D design software for the manufacturing, building and construction, and media and entertainment markets.  Since its introduction of AutoCAD software in 1982, Autodesk has developed the broadest portfolio of state-of-the-art digital prototyping solutions to help customers experience their ideas before they are real.  Fortune 1000 companies rely on Autodesk for the tools to visualize, simulate and analyze real-world performance early in the design process to save time and money, enhance quality and foster innovation.]]></description></item><item><title><![CDATA[Kynogon announces Kynapse support for WiiTM]]></title><link>http://www.capdecisif.com</link><pubDate>Tue, 04 Dec 2007 00:00:00 +0100</pubDate><description><![CDATA[Kynogon announces today Kynapse support for WiiTM. Game developers for Wii can now access all Kynapse functionalities and tools to empower their Non Player Characters with advanced behaviors.
 
Pierre Pontevia, Kynogon CEO, comments: “Wii is a remarkable success and we are proud to offer Kynapse to Wii game developers. The unique capabilities of Wii allow developers to produce creative forms of gameplay that require innovative AI. Kynapse has been selected by a very significant number of industry leaders for the development of AAA titles. With Kynapse, we feel Wii developers have another critical tool in their hands that helps them unleash the real magic of the Wii system.”
 
Kynapse offers a complete 3D pathfinding solution handling dynamic terrains and hierarchical computations. It also includes advanced spatial reasoning functionalities to dynamically identify 3D hiding positions, threatening zones, access ways, etc. On the tool side, Kynapse automates 3D pathfinding and perception data generation]]></description></item><item><title><![CDATA[Sony Online Entertainment Selects Kynapse for its DC Comics Based Action Video Game for the PC and PLAYSTATION®3 System]]></title><link>http://www.capdecisif.com</link><pubDate>Tue, 20 Nov 2007 00:00:00 +0100</pubDate><description><![CDATA[Kynogon, a market leader in AI middleware solutions for the gaming industry announces today that Kynapse is chosen by Sony Online Entertainment LLC (SOE) for the development of their massively multi-player online action game set in the DC Comics Universe, licensed by Warner Bros. Interactive Entertainment.
 
John Blakely, VP of Development at SOE’s Austin, Texas studio, sees Kynogon’s technology as instrumental in helping the development team deal with the complexities faced with online games. “We were looking for an AI solution that would be capable of dealing with dynamic large scale worlds in a seamless manner. By using Kynapse we have a powerful technology to manage extremely dynamic environments and very large maps. Our team can concentrate on the creative elements of the game faster in the development process, and thus enhance the game-play experience.”
 
Pierre Pontevia, CEO of Kynogon, added: “Sony Online Entertainment is a true leader in online gaming. They have very high standards that push technology to its limits, continuously pursuing and realizing ambitious projects. We are very excited that the Kynapse engine has been chosen for this title based in the DC Comics universe. This choice represents for us a big recognition of our technology’s capacity to deal with complex, dynamic and large environments in the online gaming segment.”
 
About Kynogon
Kynogon develops and markets Kynapse, a unique A.I. engine. Kynapse is used by the world's leading game developers such as Electronic Arts, Activision, Bethesda Softworks, Digital Illusion CE, Lionhead Studios, Real Time Worlds, SEGA, Sony Online Entertainement, Spark Unlimited, THQ and Turbine, for the development of their AAA titles. Available for the PlayStation(R)2 computer entertainment system, PLAYSTATION(R)3 computer entertainment system, and PSP(R) (PlayStation(R)Portable) system, Xbox™, Xbox360™, Wii™, GameCube™ and the PC, Kynapse has been used in the development of more than 60 of some of the best known game titles including Crackdown, Alone in the Dark 5, Fable 2, Sacred 2 and The Lord of the Rings Online™: Shadows of Angmar™. Kynapse has also been selected by industry leaders such as EADS and British Aerospace Systems as their preferred AI solution. For more information please visit www.kynogon.com.
 
About DC Comics
DC Comics, a Warner Bros. Entertainment Company, is the largest English-language publisher of comics in the world and home to such iconic characters as Superman, Batman, Wonder Woman and the Sandman. These DC super heroes and others have starred in comic books, movies, television series (both animated and live-action) and cyberspace, thrilling audiences of all ages for generations.  DC Comics’ Web site is located at www.dccomics.com <http://www.dccomics.com/>.]]></description></item><item><title><![CDATA[Maeglin Software accueille à son capital]]></title><link>http://www.capdecisif.com</link><pubDate>Mon, 12 Nov 2007 00:00:00 +0100</pubDate><description><![CDATA[Maeglin Software acquiert Ipracom, société spécialisée dans les technologies peer-to-peer de mobile à mobile et de mobile à PC. Par cette opération, Maeglin Software renforce son équipe et accueille à son capital CDC Innovation, Innovacom, et CapDecisif, trois fonds d’investissement de premier ordre.

Publier, sauvegarder et partager ses fichiers à distance de mobile à PC et de mobile à mobile 
Maeglin Software commercialise Pleex, le premier réseau social peer-to-peer mobile. Ce rapprochement avec Ipracom va permettre aux utilisateurs de Pleex d’effectuer à distance échanges de fichiers et synchronisations entre :
leur mobile et leur PC
leur mobile et les mobiles des autres Pleexeurs 

Concrètement, les Pleexeurs pourront, en un clique, publier sur un site Web leurs photos et leurs vidéos prisent depuis leur mobile. Ils pourront sauvegarder le répertoire de leur mobile sur leur PC. Ils pourront enfin facilement partager avec leurs amis leurs fichiers depuis un mobile, via le réseau data opérateur. Ce partage de fichiers, bien connu des internautes fréquentant les sites du Web 2.0, sera pour la première fois disponible auprès des mobinautes.   
 
La technologie Ipracom, déjà opérationnelle, sera portée et intégrée dans Pleex courant 2008. Charles-Edouard Ruault, Directeur Technique de Maeglin Software déclare « la technologie Ipracom est un complément naturel pour Pleex, qui ajoute ainsi à l’échange par Bluetooth entre ‘univers de proximité’, les échanges par data entre ‘univers distants’. »
 
CDC Innovation, Innovacom, et CapDecisif au Capital de Maeglin Software 
Ce rapprochement annonce la venue de trois investisseurs de référence au capital de Maeglin Software : CDC Innovation, filiale du groupe Caisse des Dépôts, Innovacom, filiale capital-risque du groupe France Telecom, et CapDecisif, fonds d’amorçage en Ile de France. Franck Noiret, General Partner de CDC Innovation ajoute « nous avons hâte de travailler avec l’équipe de Maeglin Software dans le développement de Pleex et voulons lui donner les moyens de réussir. » 
 
À propos de Maeglin Software 
Maeglin Software développe et commercialise Pleex, le premier réseau social peer-to-peer mobile. La société est implantée à Paris et à Montpellier (France) au sein de Cap Oméga, « meilleur incubateur mondial de l’année 2007 ». Maeglin Software a pour investisseurs CDC Innovation, Innovacom et Cap Décisif et bénéficie du support de la Région Languedoc-Roussillon et de Oséo Innovation. Pour en savoir plus : www.maeglin.com]]></description></item><item><title><![CDATA[SEQUANS WINS BEST CHIP DESIGN AWARD FROM WIMAX WORLD USA]]></title><link>http://www.capdecisif.com</link><pubDate>Thu, 27 Sep 2007 00:00:00 +0100</pubDate><description><![CDATA[xchange magazine announced today that Sequans Communications has been named winner of the Best of WiMAX World USA 2007 Award for Chip Design. Sequans won for its SQN1130 Mobile WiMAX subscriber station chip that delivers industry-leading high throughput with low power consumption and superior receiver sensitivity.

“We are very pleased to win the best chip design award and we congratulate all the winners and runners-up, especially our customers, Airspan, Redline, Telsima, WiNetworks, and ZyXel,” said Georges Karam, Sequans CEO.  “It is thrilling to see our chips in more and more WiMAX systems, devices, and networks around the world and we are grateful to have our technology recognized by the WiMAX community.  Thank you to xchange magazine, Trendsmedia, and all the distinguished judges.”

Sequans received its best chip design award last night at a ceremony following the close of the WiMAX World expo floor. Eliot Weinman, conference co-chair and president of Trendsmedia, the events and publishing division of Yankee Group that produces WiMAX World, along with Paula Bernier, editor in chief, and Tara Seals, associate editor, of xchange, presented the awards in seven categories. Sequans and their award will be featured in the November issue of xchange, as well as on the WiMAX World and xchange Web sites.

Sequans’ award-winning SQN1130 chip delivers throughput of greater than 30 Mbps on a single terminal with power consumption of less than 280 mW.  This extraordinary performance is a function of Sequans’ mimoMAX™ technology, based on a unique, patent-pending Sequans algorithm.  mimoMAX combines a true maximum likelihood (ML) MIMO decoder on the downlink, enabling highest performance and lowest power consumption, with two transmitters on the uplink, enabling MIMO on the uplink for additional link budget improvement.  The SQN1130 also delivers superior receiver sensitivity, up to 13 dB higher than what is required by the Mobile WiMAX profile, for larger cell coverage and better in-building penetration.

Sequans and the other WiMAX World award winners were selected by an independent panel of judges, including Craig Mathias, principal, Farpoint Group; Will Strauss, principal analyst, Forward Concepts; Adlane Fellah, CEO and founder, Maravedis Inc.; Caroline Gabriel, lead research analyst, Rethink Research; Philip Marshall, vice president of enabling technologies, Yankee Group; James Farstadt, founder and president, rClient LLC; Michael Khalilian, chairman and president, IMS Forum; and representatives from xchange and Trendsmedia.

For a complete list of winners, visit www.xchangemag.com/wimaxusa2007.]]></description></item><item><title><![CDATA[DBV TECHNOLOGIES EXPANDS MANAGEMENT TEAM AND MOVES TO NEW FACILITIES IN PARIS]]></title><link>http://www.capdecisif.com</link><pubDate>Mon, 17 Sep 2007 00:00:00 +0100</pubDate><description><![CDATA[DBV Technologies (DBV), a biopharmaceutical company engaged in the development of non-invasive  epicutaneous delivery technology and products, has announced today that it has expanded its management team with three major appointments. The Company has also moved to new facilities in central Paris, while maintaining its registered site in Boulogne on the outskirts of Paris. DBV is developing its proprietary, patented VIASKIN® epicutaneous delivery technology primarily for the diagnosis and treatment of allergies.
Dr. Hing Kin Chan joins DBV as Chief Business Officer from ProBioGen AG in Germany where he was Vice President of Commercial Development. In this role, Dr. Chan was responsible for securing out-licensing contracts with biotechnology companies and big pharma. Previous industry business development roles were at Eurand International S.p.A, IDEA AG, Colorcon and Lohmann Therapie Systeme. With his valuable past industry experience specifically in drug delivery, Dr. Chan will play a key role in securing partnership agreements with industry for DBV’s technologies and products. 
Dr Florian Reinaud has joined DBV as its first serving Chief Financial Officer. Previously he worked at Apax Partners where he advised on and executed both venture and late stage investments in the healthcare field. Prior to this, Dr. Reinaud worked as an analyst with Schroder Salomon Smith Barney (Citigroup). As CFO, Dr. Reinaud will help secure future financings to help take DBV’s further products on to the market. Dr Reinaud holds a BA(hons) from Oxford University and a medical degree from Imperial College School of Medicine, London, UK.
Finally, Dr. Laurent Martin is welcomed to DBV as Regulatory Affairs Director. He previously worked at Orphan Europe, a company specialised in the marketing of orphan drugs where his responsibilities were divided between Regulatory Affairs and Quality Assurance. At DBV, Dr. Martin will use his international regulatory affairs experience and knowledge of the pharmaceutical industry gained at Galderma, Fournier and Guerbet to co-ordinate worldwide registration of DBV’s pharmaceutical products. Dr. Martin holds an MBA from IAE Paris Sorbonne and received his Masters in Public Health Law from the Faculty of Sceaux, France. Dr. Martin graduated as a pharmacist at the University Rene Descartes, Paris, France.
Commenting on these appointments, Jean-François Biry, Chairman and CEO of DBV, said, “We are delighted that we have been able to attract three such talented and experienced new employees to the Company who will be integral to the future growth and development of DBV.”
In conjunction with these managerial appointments, DBV has also moved its operational facilities to a new and larger site near Hospital Cochin in central Paris. The Company will run all R&D operations from the new location. The new building has capacity to house 80 people, enabling DBV to expand its workforce in line with the planned expansion of its in-house R&D programs. These changes in management and location reflect DBV’s rapid growth since bringing its first product Diallertest® for cow’s milk allergy onto the market in France.]]></description></item><item><title><![CDATA[ERYtech Pharma se renforce et se]]></title><link>http://www.capdecisif.com</link><pubDate>Mon, 16 Jul 2007 00:00:00 +0100</pubDate><description><![CDATA[ERYtech Pharma, société spécialisée dans l’encapsulation de médicament dans les globules rouges, 
annonce qu’elle lance l’essai clinique GRASPALL en Belgique, visant à évaluer son produit 
GRASPA® dans la récidive de la leucémie aigüe lymphoblastique.  
La société biopharmaceutique vient de recevoir l’accord de l’Agence Fédérale Belge des Médicaments 
et Produits de Santé pour le démarrage de l’étude GRASPALL en Belgique, première étape de son 
développement clinique international. 
 
Suite à sa levée de fonds de 12 millions d’euros réalisée en décembre 2006, ERYtech Pharma 
poursuit ses projets de développement et s’est entourée de nouveaux collaborateurs hautement 
qualifiés. 
Dans ce contexte d’évolution rapide, ERYtech Pharma renforce également sa direction et 
internationalise son Conseil de Surveillance. 
 
 
Corinne DUGUET, en tant que Directeur Médical. 
 
Le Docteur Corinne Duguet, a occupé différentes fonctions dirigeantes dans l’industrie 
pharmaceutique dont Responsable Médical Communication et Formation  chez Celgène France, 
Directeur du Développement Clinique / Europe de Pharmion et Directeur Médical chez Laphal. 
Dotée d’une excellente expertise dans  le développement  de médicaments orphelins en Oncologie et 
Hématologie, elle est titulaire d’un doctorat de Médecine de l’Université Paris V, CHU Necker Enfants 
Malades. 
 
 
Lennart BRUCE, en tant que nouveau membre du Conseil de Surveillance. 
 
Le Docteur Bruce a occupé différentes fonctions de Directeur en ‘’Business Development’’, en 
Marketing International, en Développement Clinique dans l’industrie pharmaceutique.  
Co-fondateur et ancien Vice Président senior ‘’Corporate Development’’ de Biovitrum, il a également 
été Vice Président ‘’Global Licensing’’ de Pharmacia. 
Le Docteur Bruce est également membre du Conseil de Surveillance de Helperby Therapeutics au 
Royaume-Uni, de  Pharmapnea et de Laccure en Suède. 
Il a créé et dirige aujourd’hui VIKEN Pharma Consulting. 
Il est titulaire d’un doctorat en Zoophysiologie de l’Université de Lund, Suède. 
 
 
Philippe ARCHINARD, en tant que nouveau membre du Conseil de Surveillance. 
 
Le Docteur Archinard a occupé différentes fonctions en Management et en ‘’Business Development’’ 
en  Europe et aux-Etats-Unis. 
Ancien PDG d’Innogenetics, il est aujourd’hui, PDG chez Transgène et Directeur Scientifique chez  
Mérieux Alliance Group (bioMérieux, Silliker, Shantha Biotechnics, Transgene et Advanced 
BioScience Laboratories). 
Il assure la Présidence de Lyon BioPole et a présidé France Biotech. 
Il est titulaire d’un doctorat en biochimie  de l’Université de Lyon et a terminé le programme PMD de 
l’école de commerce d’Harvard. 
« Comme prévu, le développement du GRASPA® se poursuit avec très prochainement l’implication 
de médecins investigateurs en Belgique.  L’expérience de Corinne nous sera très précieuse dans le 
cadre du développement clinique international du GRASPA®.», déclare Yann GODFRIN, Président du 
Directoire et Directeur Scientifique, qui ajoute : « ERYtech Pharma croît rapidement et devrait compter 
20 personnes au 1er janvier prochain ». 
 
« Sur un autre plan, Lennart et Philippe vont contribuer à notre développement international », 
complète Pierre-Olivier GOINEAU, Directeur Général : « Nous avons beaucoup avancé et avons 
développé de nouvelles preuves de concept in vivo, susceptibles d’intéresser l’industrie 
pharmaceutique. Nous sommes maintenant structurés pour nouer ce type d’alliances ». 
 
Suite à l’accord des autorités belges, le Professeur Alina Ferster, responsable de l’unité d’onco- 
hématologie de l’hôpital des enfants Reine Fabiola (Bruxelles) déclare : « Nous attendions avec 
impatience la possibilité d’inclure nos patients dans l’étude GRASPALL. Ce produit est très prometteur 
quand à l’amélioration de l’indexe thérapeutique de l’asparaginase ».]]></description></item><item><title><![CDATA[First Functional-Knock-Out in Rat Species]]></title><link>http://www.capdecisif.com</link><pubDate>Thu, 19 Apr 2007 00:00:00 +0100</pubDate><description><![CDATA[Nokad announced today that Amine ABINA, President and Chief Executive
Officer will present new
results of functional-Knock-Out in the Rat species at Charles River
laboratories Seminar in Evry on April
4th at 9:15 am. 
 
Dr ABINA will present the first functional-Knock-Out Nokad obtained in this
species, after multiple successfull
models generated in mice, using its new proprietary immune based technology.
The results obtained in this model, allowed the discovery of a new
Erythropoietin-receptor pathway.
 
NOKAD is the first company to provide a full functional Knock-Out strategy
in all mammals based on an
immunological strategy.
  
This proprietary technology, today used by different pharmaceutical
companies, had advantages to accelerate in
vivo target validation and functional discoveries in the most relevant
animal model or species. Testing synergies,
interactions using the NOKAD strategy by doing in the same experiment, a
Knock-Out on another Knock-Out,
multiple Knock-Outs, a Knock-Out on a transgenic animal, a Knock-Out on a
disease model (ob/ob, db/db, cancer
models,...), Knock-Outs in different species, are now possibilities that are
already performed simultaneously in
the Nokad programs.
  
www.nokad-technology.com
 
For more informations:
Contact@nokad-technology.com]]></description></item><item><title><![CDATA[Siemens selects Sequans' mobile WiMAX chip]]></title><link>http://www.capdecisif.com</link><pubDate>Tue, 27 Mar 2007 00:00:00 +0100</pubDate><description><![CDATA[EQUANS Communications, a leading supplier and developer of fixed and mobile WiMAX semiconductor solutions, announced that Siemens, one of the world’s largest consumer communications device manufacturers, will use Sequans’ newly released mobile WiMAX Wave 2 chips to build WiMAX residential modems and gateways. The units are being developed by Siemens Home and Office Communications Device division and are part of the company’s Gigaset product family. Siemens is a global leader in fixed WiMAX consumer devices, with mobile WiMAX development well underway.

“Sequans’ SQN1130 mobile WiMAX chips enable us to build the highest performing WiMAX modems with industry-leading throughput,” said Marc Achhammer, senior vice president, head of WiMAX, Siemens Home and Office Communication Devices. “We are dedicated to WiMAX as a key global broadband technology, and Sequans supports our strategy and roadmap for mobile WiMAX the best.”

The new Sequans chip, the SQN1130, includes all MAC and PHY features required by the 802.16e Wave 2 standard, including full 2X2 MIMO, plus a low complexity implementation of MIMO — unique to Sequans — that delivers the highest possible performance while minimizing power consumption. Sequans’ SQN1130 delivers more than 30 Mbps total throughput.

“We are honored to be working with Siemens and pleased to support their dedication to enhancing users’ broadband experience with WiMAX,” said Georges Karam, Sequans CEO. “Siemens is one of the few major solution vendors with global reach, a leading position in the market, and proven success in the consumer space with devices such as cordless phones, VOIP phones, and DSL gateways.”

About Siemens Home and Office Communications Devices

Siemens Home and Office Communication Devices GmbH & Co KG is a wholly-owned subsidiary of Siemens AG. The company focuses on the design, development, manufacturing and distribution of the full range of Siemens Gigaset products, including cordless phones, home media devices and broadband products and services which enable seamless, integrated communication solutions for operators and consumers. The company operates worldwide with a fiscal year’s revenue stream (September 30, 2006) of approximately 960 million euros. More about Siemens Home and Office Communication Devices at www.siemens.com/gigaset.]]></description></item><item><title><![CDATA[VOLUNTIS BOUCLE SON TOUR DE TABLE DE 2.000.000 EUROS AVEC CIC VIZILLE CAPITAL]]></title><link>http://www.capdecisif.com</link><pubDate>Thu, 01 Feb 2007 00:00:00 +0100</pubDate><description><![CDATA[VOLUNTIS, éditeur de logiciels de gestion de la relation patient, annonce avoir bouclé son tour de table 
de 2.000.000 Euros initié avec Cap Decisif, avec les fonds d’investissement CIC Vizille Capital Innovation, 
et SHAM.   
 
Ce premier tour de table institutionnel va permettre à Voluntis de renforcer sa présence en Europe tout en 
dynamisant le développement de sa gamme de logiciels medpassport. 
  
D’ores et déjà, les industriels de la santé, les assureurs et les prestataires de soins utilisent medpassport 
pour déployer des solutions d’accompagnement et de suivi des patients, dans un contexte multinational. 
Le secteur de la gestion de la relation patient est en forte croissance en Europe et en Amérique du Nord. 
Les industriels et les assureurs proposent ainsi de plus en plus fréquemment aux patients des services de 
suivi et d’accompagnement entre les consultations médicales, via différents canaux (coaching 
téléphonique, visites à domicile, appareils de mesure communicants, courriers, e-mails, services mobiles). 
Ces solutions favorisent l’observance et le bon usage des traitements, garantissent une meilleure 
efficacité des produits de santé en utilisation courante, et contribuent à la réduction des complications des 
maladies chroniques, dont la prise en charge est extrêmement coûteuse pour les systèmes de santé. 
 
« Nous sommes ravis que CIC Vizille Capital Innovation, et SHAM aient rejoint Cap Decisif et nos 
investisseurs privés au capital de Voluntis », déclare  Pierre Leurent, Président Directeur Général et 
Fondateur de Voluntis. « Cette levée de fonds va nous permettre d’intensifier notre développement 
européen en vue de devenir le numéro 1 du domaine dans les 3 ans à venir. Nous allons aussi renforcer 
notre effort de recherche et développement pour maintenir l’avance de medpassport sur le marché du 
PRM. » 
 
« Dans un marché du PRM encore émergent, Voluntis a déjà montré sa capacité à contracter avec de 
grands comptes. Cette levée de fonds doit maintenant lui permettre de conforter son positionnement et 
d’accélérer son développement commercial notamment à l’international », ajoute Ludovic André, CIC 
Vizille Capital Innovation  
 
« Par cet investissement, SHAM souhaite donner à Voluntis les moyens de financer son développement 
de produits innovants dans le domaine de la santé, secteur que nous connaissons bien en tant 
qu'assureur leader en RC médicale » déclare Jean-Yves NOUY, Directeur Général, SHAM.]]></description></item><item><title><![CDATA[Sustainable UGC business model a reality with]]></title><link>http://www.capdecisif.com</link><pubDate>Sun, 07 Jan 2007 00:00:00 +0100</pubDate><description><![CDATA[Advestigo’s patented Theraography™ technology to secure the future of online video sharing


Paris, France, January, 22nd – Advestigo, a major provider of content recognition technology, launches AdvestiGATE™ to automatically filter copyrighted files uploaded to user-generated content (UGC) websites.

Sustainable UGC business model
Video sharing websites, which might handle upwards of 65,000 newly uploaded clips every day, are permanently at risk of litigation by unintentionally distributing copyrighted content online. AdvestiGATE automatically filters uploaded content, putting a stop to accidental copyright infringement. Until now, this has been impossible. UGC websites can now develop sustainable, profitable business models without the risk of litigation, and copyright owners can safely decide how and where they want their content to be used.

Award-winning* digital fingerprinting technology
AdvestiGATE uses Advestigo’s patented Theraography™ technology to calculate a fingerprint for each uploaded video file. AdvestiGATE then automatically cross-references new fingerprints against a database of existing fingerprints from copyrighted material; in a matter of seconds, files that contain full or partial, perfect or degraded copies of copyrighted content will be identified and flagged.

AdvestiGATE can manage video and audio in one comprehensive solution. For audio files, it relies either on Advestigo’s audio fingerprint technology or interoperates with existing audio recognition technologies.

“Our technology, which is already in industrial use around the world - embedded in our range of peer-to-peer monitoring solutions - is shaping the future of online video sharing,” says Michel Roux, President and CEO of Advestigo.

Off-the-shelf solution
AdvestiGATE is delivered on a plug-and-play 1U rackable appliance for seamless integration into existing UGC infrastructure. Scalability is assured through multiple appliances within a single process. Prices start at 15,900 USD plus subscription to a fingerprint database. 

About Advestigo
Advestigo is a technology leader in the fast-growing digital asset management market. Using Theraography, a unique technology that analyses digital content to generate content-based "fingerprints", Advestigo provides solutions to automatically monitor and identify multimedia content.

* Advestigo’s AdvestiSEARCHTM, which is based on Theraography technology, won the European Information Society Technologies (IST) Grand Prize in 2006.]]></description></item><item><title><![CDATA[Motorola investit dans Sequans]]></title><link>http://www.capdecisif.com</link><pubDate>Wed, 29 Nov 2006 00:00:00 +0100</pubDate><description><![CDATA[SEQUANS Communications, a leading supplier and developer of fixed and mobile WiMAX semiconductor solutions, has received substantial investment capital from Motorola, Inc. (NYSE: MOT), through Motorola Ventures, its strategic venture capital arm.  The investment is an extension of Sequans? recent round of funding announced in July.

?We are delighted to be investing in a company which has demonstrated leadership in WiMAX silicon,? said John O?Donohue, managing director, Motorola Ventures in Europe. ?This demonstrates Motorola Ventures? commitment to investing in world class technology companies as part of the strategy of delivering Wi4, Motorola?s next generation wireless solutions to the marketplace.? 

?Motorola is the foremost WiMAX equipment maker and we are grateful for their support as we continue to meet our aggressive development schedule,? said Georges Karam, Sequans CEO.  ?Our collaboration will help to accelerate the growing WiMAX momentum and will have a direct impact on the rollout of WiMAX networks, providing high bandwidth and mobility to people around the world.?

Sequans has been heavily involved with the development of IEEE 802.16 standards and WiMAX Forum activities, including all PlugFests and certification procedures.  Sequans recently announced the general availability of its mobile WiMAX chip (SQN1110) for client devices.   The chip features the industry?s lowest power consumption, drawing a mere 350mW of power, and delivers a throughput of more than 10 Mbps.  Sequans also provides a base station solution for mobile WiMAX (SQN2110), as well as a base station and subscriber station chips for fixed WiMAX (SQN2010, SQN1010).  Sequans will deliver in Q1 2007 a mobile WiMAX chip (SQN 1130) for client devices designed to exceed WiMAX Forum Wave 2 certification requirements.

About Motorola Ventures
Motorola Ventures (MV) is the global, strategic venture capital investment arm of Motorola, Inc. MV actively invests at all stages in developing companies of strategic value to Motorola in order to accelerate access to new technologies, new markets and new talent. For more information: www.motorola.com/ventures 

About Motorola
Motorola is known around the world for innovation and leadership in wireless and broadband communications. Inspired by our vision of Seamless Mobility, the people of Motorola are committed to helping you get and stay connected simply and seamlessly to the people, information, and entertainment that you want and need. We do this by designing and delivering "must have" products, "must do" experiences and powerful networks -- along with a full complement of support services. A Fortune 100 company with global presence and impact, Motorola had sales of US $36.8 billion in 2005. For more information about our company, our people and our innovations, please visit www.motorola.com.]]></description></item></channel></rss>